Expression, purification, characterization, and cytotoxic evaluation of the ML1-STxB fusion protein.
Anticancer
E. coli
Fusion protein
ML1-STxB
SkBr3
rML1-STxB
Journal
Archives of microbiology
ISSN: 1432-072X
Titre abrégé: Arch Microbiol
Pays: Germany
ID NLM: 0410427
Informations de publication
Date de publication:
06 May 2023
06 May 2023
Historique:
received:
30
01
2023
accepted:
20
04
2023
revised:
18
04
2023
medline:
8
5
2023
pubmed:
6
5
2023
entrez:
6
5
2023
Statut:
epublish
Résumé
Targeted delivery of a toxin substance to cancer cells is one of the most recent cancer treatment options. Mistletoe Lectin-1 (ML1) in Viscum album L. is a Ribosome-inactivating proteins with anticancer properties. Therefore, it appears that a recombinant protein with selective permeability can be generated by fusing ML1 protein with Shiga toxin B, which can bind to Gb3 receptor that is abundantly expressed on cancer cells. In this study, we sought to produce and purify a fusion protein containing ML1 fused to STxB and evaluate its cytotoxic activities. The ML1-STxB fusion protein coding sequence was cloned into the pET28a plasmid, then was transformed into E. coli BL21-DE3 cells. Following induction of protein expression, Ni-NTA affinity chromatography was used to purify the protein. Using SDS-PAGE and western blotting, the expression and purification processes were validated. On the SkBr3 cell line, the cytotoxic effects of the recombinant proteins were evaluated. On SDS-PAGE and western blotting membrane, analysis of purified proteins revealed a band of approximately 41 kDa for rML1-STxB. Ultimately, statistical analysis demonstrated that rML1-STxB exerted significant cytotoxic effects on SkBr3 cells at 18.09 and 22.52 ng/L. The production, purification, and encapsulation of rML1-STxB fusion protein with potential cancer cell-specific toxicity were successful. However, additional research must be conducted on the cytotoxic effects of this fusion protein on other malignant cell lines and in vivo cancer models.
Identifiants
pubmed: 37148384
doi: 10.1007/s00203-023-03563-3
pii: 10.1007/s00203-023-03563-3
doi:
Substances chimiques
Lectins
0
Recombinant Proteins
0
Antineoplastic Agents
0
Biological Products
0
Recombinant Fusion Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
220Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Allen TM, Mumbengegwi DR, Charrois GJ (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11(9):3567–3573
doi: 10.1158/1078-0432.CCR-04-2517
pubmed: 15867261
Asrorov AM et al (2019) Advances on tumor-targeting delivery of cytotoxic proteins. ACS Pharmacol Transl Sci 3(1):107–118
doi: 10.1021/acsptsci.9b00087
pubmed: 32259092
pmcid: 7089019
Bergan J et al (2012) Shiga toxins. Toxicon 60(6):1085–1107
doi: 10.1016/j.toxicon.2012.07.016
pubmed: 22960449
Bolognesi A et al (2016) Ribosome-inactivating proteins from plants: a historical overview. Molecules 21(12):1627. https://doi.org/10.3390/molecules21121627
doi: 10.3390/molecules21121627
pubmed: 27898041
pmcid: 6273060
Celi AB et al (2022) Role of globotriaosylceramide in physiology and pathology. Front Mol Biosci 9:104
doi: 10.3389/fmolb.2022.813637
Dietrich JB et al (1992) Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs 3(5):507–11
doi: 10.1097/00001813-199210000-00010
pubmed: 1450445
Engedal N et al (2011) Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol 4(1):32–46
doi: 10.1111/j.1751-7915.2010.00180.x
pubmed: 21255370
Gabius HJ et al (2001) Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19(2):114–126
doi: 10.1081/CNV-100000146
pubmed: 11296616
Gariepy J (2001) The use of Shiga-like toxin 1 in cancer therapy. Crit Rev Oncol Hematol 39(1–2):99–106
doi: 10.1016/S1040-8428(01)00126-3
pubmed: 11418306
Huldani H et al (2022) Concanavalin A as a promising lectin-based anti-cancer agent: the molecular mechanisms and therapeutic potential. Cell Commun Signal 20(1):1–14
doi: 10.1186/s12964-022-00972-7
Johannes L, Römer W (2010) Shiga toxins–from cell biology to biomedical applications. Nat Rev Microbiol 8(2):105–116
doi: 10.1038/nrmicro2279
pubmed: 20023663
Johansson D et al (2009) Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer 9:67
doi: 10.1186/1471-2407-9-67
pubmed: 19245689
pmcid: 2650710
Kourmanova AG et al (2004) Cloning and characterization of the genes encoding toxic lectins in mistletoe (Viscum album L). Eur J Biochem 271(12):2350–2360
doi: 10.1111/j.1432-1033.2004.04153.x
pubmed: 15182350
LaCasse EC (1999) Shiga-like toxin-1 receptor on human breast cancer, lymphoma, myeloma and absence from CD34(+) hematopoietic stem cells: implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 94(8):2901–2910
pubmed: 10515895
Lu JQ et al (2020) Engineering of ribosome-inactivating proteins for improving pharmacological properties. Toxins (Basel) 12(3):167
doi: 10.3390/toxins12030167
pubmed: 32182799
MasoudiKerahroudi M, Honari H, Abdollahi M (2017) Expression of Blf1-Stx B gene cassette in E. coli and investigation antibody titer in mice. J Shahid Sadoughi Univ Med Sci 24(11):876–886
Milius S (2000) Botany under the mistletoe: twisters, spitters, and other flowery thoughts for romantic moments. Sci News 158(26–27):411–413
doi: 10.2307/4018592
Nielsen K, Boston RS (2001) Ribosome-inactivating proteins: a plant perspective. Annu Rev Plant Physiol Plant Mol Biol 52(1):785–816
doi: 10.1146/annurev.arplant.52.1.785
pubmed: 11337416
Puri M et al (2012) Ribosome-inactivating proteins: current status and biomedical applications. Drug Discov Today 17(13–14):774–783
doi: 10.1016/j.drudis.2012.03.007
pubmed: 22484096
RahnamaieYahyaabadi S et al (2019) Subcloning and expression of ML1-stxB fusion gene of mistletoe lectin in E. coli and production of its antibody in mouse. Qom Univ Med Sci J 12(12 #f00808):42–52
Stirpe F (2004) Ribosome-inactivating proteins. Toxicon 44(4):371–383
doi: 10.1016/j.toxicon.2004.05.004
pubmed: 15302521